Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D)

被引：0
|
作者：
Raskin, P
Dole, JF
Rappaport, EB
机构：
来源：
DIABETES | 1999年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0404
引用
收藏
页码：A94 / A94
页数：1
相关论文
共 50 条
  • [21] The Impact of Electronic Consultation (EC) on Glycemic Control in Type 2 Diabetes (T2D)
    Morariu, Elena M.
    Bandi, Archana
    Derubertis, Frederick
    Rao, R. Harsha
    DIABETES, 2016, 65 : A318 - A318
  • [22] Benefits of rosiglitazone (RSG) plus metformin (MET) vs MET uptitration in older patients (Pts) with type 2 diabetes (T2D)
    Garber, Alan J.
    Rood, Julie A.
    Waterhouse, Brian R.
    Wolstenholme, Allen R.
    Cobitz, Alexander R.
    Rosenstock, Julio
    DIABETES, 2006, 55 : A476 - A477
  • [23] Correlations between plasma glucose (PG) measures and HbA, in insulin-treated patients (pts) with type 2 diabetes (T2D)
    Ilag, L.
    Choi, S.
    Carey, M.
    Shrom, D.
    Heine, R.
    DIABETOLOGIA, 2008, 51 : S432 - S432
  • [24] Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone
    Garg, Ranjna
    Gopal, Jayanthi
    Jones, Geraint Rhys
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (01) : 1 - 6
  • [25] Repaglinide with bedtime insulin improves glycaemic control in poorly controlled type 2 diabetes
    Brogard, JM
    Landin-Olsson, M
    Eriksson, J
    DIABETOLOGIA, 2000, 43 : A186 - A186
  • [26] Aleglitazar (ALE) Improves Insulin Sensitivity, Glucose Control, and Lipids in People with Type 2 Diabetes (T2D)
    Stirban, Alin O.
    Andjelkovic, Mirjana
    Heise, Tim
    Nosek, Leszek
    Fischer, Annelie
    Gastaldelli, Amalia
    Herz, Matthias
    DIABETES, 2014, 63 : A291 - A291
  • [27] Mechanisms by which rosiglitazone improves glycemic control in type 2 diabetes mellitus
    Dostou, JM
    Islam, N
    Meyer, C
    Woerle, HJ
    Sparks, C
    Sparks, J
    Wittlin, S
    Dabiri, GA
    Anderson, AB
    Gerich, J
    DIABETES, 2001, 50 : A513 - A513
  • [28] Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes
    Lauffenburger, Julie C.
    Lewey, Jennifer
    Jan, Saira
    Lee, Jessica
    Ghazinouri, Roya
    Choudhry, Niteesh K.
    JAMA NETWORK OPEN, 2020, 3 (01)
  • [29] Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes: Empowerment Perceptions and Diabetes Distress as Important Determinants
    Chen, Shi-Yu
    Hsu, Hui-Chun
    Wang, Ruey-Hsia
    Lee, Yau-Jiunn
    Hsieh, Chang-Hsun
    BIOLOGICAL RESEARCH FOR NURSING, 2019, 21 (02) : 182 - 189
  • [30] Comparison of resources utilization (RU) and cost in drug naive type 2 diabetes (T2D) patients treated with rosiglitazone (RSG) vs. sulfonylurea (SU) monotherapy
    Duh, M. S.
    Gosselin, A.
    Beaulieu, N.
    Arana, L. M.
    Arondekar, B.
    VALUE IN HEALTH, 2008, 11 (03) : A223 - A223
12345